Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial

Abstract

Aging is a major risk factor for the majority of human diseases, and the development of interventions to reduce the intrinsic rate of aging is expected to reduce the risk for age-related diseases including cardiovascular disease, cancer, and dementia. In the skin, aging manifests itself in photodamage and dermal atrophy, with underlying tissue reduction and impaired barrier function. To determine whether rapamycin, an FDA-approved drug targeting the mechanistic target of rapamycin (mTOR) complex, can reduce senescence and markers of aging in human skin, an exploratory, placebo-controlled, interventional trial was conducted in a clinical dermatology setting. Participants were greater than 40 years of age with evidence of age-related photoaging and dermal volume loss and no major morbidities. Thirty-six participants were enrolled in the study, and nineteen discontinued or were lost to follow-up. A significant ( P = 0.008) reduction in p16 INK4A protein levels and an increase in collagen VII protein levels ( P = 0.0077) were observed among participants at the end of the study. Clinical improvement in skin appearance was noted in multiple participants, and immunohistochemical analysis revealed improvement in histological appearance of skin tissue. Topical rapamycin reduced the expression of the p16 INK4A protein consistent with a reduction in cellular senescence. This change was accompanied by relative improvement in clinical appearance of the skin and histological markers of aging and by an increase in collagen VII, which is critical to the integrity of the basement membrane. These results indicate that rapamycin treatment is a potential anti-aging therapy with efficacy in humans. Trial registration ClinicalTrials.gov Identifier: NCT03103893.

Cited by papers we hold 7

• Aging in the dermis: Fibroblast senescence and its significance · 2023
  No notice
• Skin aging from mechanisms to interventions: focusing on dermal aging · 2023
  No notice
• Skin Immunosenescence and Type 2 Inflammation: A Mini-Review With an Inflammaging Perspective · 2022
  Not checked
• Photoaging: UV radiation-induced inflammation and immunosuppression accelerate the aging process in the skin · 2022
  No notice
• CC-223, NSC781406, and BGT226 Exerts a Cytotoxic Effect Against Pancreatic Cancer Cells via mTOR Signaling · 2020
  Not checked
• Immune Clearance of Senescent Cells to Combat Ageing and Chronic Diseases · 2020
  No notice
• Effect of rapamycin on aging and age-related diseases—past and future · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.